Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2020-03-01
Saila:International Journal of Molecular Sciences
Gaiak:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Sarrera elektronikoa:https://www.mdpi.com/1422-0067/21/7/2275
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak